Our mission is to bring the groundbreaking cancer research of Dr. Theodore Lampidis through the necessary clinical trials so that this innovative treatment protocol can begin to help cancer sufferers worldwide.
Dr. Lampidis’ laboratory at the University of Miami has gained international recognition and leadership in the exploitation of increased glucose metabolism in cancer cells using the sugar analog 2-deoxy-D-glucose (better known as 2-DG) as a universal treatment for cancer. The problem: It is well established that by interfering with the dividing machinery of cells, traditional anti-cancer dugs kill the most rapidly dividing cells regardless of whether they are normal or cancerous. Consequently, chemotherapy is toxic to the most rapidly dividing normal cells in the body i.e. hair, bone marrow (where blood cells are made) and gut. Unfortunately, cancer drugs not only cause life-threatening side effects, but due to the nature of the way they act, cannot adequately kill the slow-growing metastatic population of cells invariably found in most if not all solid tumors. Furthermore, the newer targeted therapies, due to heterogeneity within tumors, are also limited in their ability to work effectively.
The solution: Molecular biology has demonstrated that all the major genes (oncogenes) responsible for driving cancer also increase glucose uptake within all tumor cells regardless of their origin. For the past 15 years, Dr. Lampidis has investigated and developed the use of 2-DG, a simple analog of sugar, to inhibit glycolysis, which the most malignant cancer cells found in the inner core of all solid cancers rely on to survive due to abnormally low levels of oxygen. More recently, he has demonstrated that using a combination of 2-DG and fenofibrate (a compound that has been safely used in humans for over 40 years to lower cholesterol and triglycerides), simultaneously provokes two types of stress, known as energy and ER stress, which most of the cancer types tested cannot overcome. As a result, the entire tumor can effectively be targeted and killed without the use of toxic chemotherapy.
Success to date: This unique combination of 2-DG and fenofibrate delivers a non-toxic treatment that has so far been shown to be effective in in vivo and in vitro studies in a wide variety of human cancers. Furthermore, Dr. Lampidis has developed a delivery mechanism (slow-release pump) that has been shown to be effective in mouse models of human cancers, providing the background for taking this technology to the next phase of clinical trials. Our hope is to be able to bring this non-toxic treatment to millions of cancer patients worldwide.
Why we need your support: Unfortunately, despite a very promising and successful Phase I clinical trial, we have hit a major roadblock in our funding. The sad reality is that given the non-patentable nature of 2-DG and the resulting dis-incentive to the pharmaceutical industry, not to mention politics and conflicts of interest within grant setting bodies, our funding has dried up. Thus, we have had to resort to philanthropy and the tireless work of volunteers to raise awareness of our cause and to bring this universal cancer treatment through the remaining phases of clinical trials to make it available to patients.
If you are interested in supporting this vital work and helping us bring a universal, non-toxic treatment to cancer sufferers worldwide, please donate today.